16. May 2012 15:46
A new pharma company specialising in drug delivery mechanisms has launched in the UK.
Adeptio Pharmaceuticals plans to adapt drugs that are already on the market to address specialist hospital-driven disease areas.
Its Board of Directors contains several experienced industry leaders with particular expertise in managing drug development within neurology and dermatology.
CEO Ian Montague (pictured) has over 20 years’ experience in the pharma industry, having held senior roles at Valeant, Abbott and Roche.
Other Board members include Henry Wendt III CBE, former Chairman of SmithKline Beecham; Handel Evans, former senior executive of IMS International; and Mark Evans, former CEO of Cambridge Laboratories.
Adeptio expects “to accelerate product time to market launch,” according to Ian Montague. “We aim to reduce the inherent risks of product development and secure long-term protection of intellectual property, thus creating and adding value through the research and development process.”